AstraZenecaNoblesville, IN
Disclosure information not submitted.
2973 - mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible
Tuesday, October 1, 202412:45 PM – 2:00 PM ET
